RGEN · Repligen Corp

Track RGEN — free

$165.05 -3.48 (-2.06%) At close · Sep 9

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$9.31B

56.44M

Up next

Next earnings call

Oct 24, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$785.10M

Trailing 12 months

Net income (TTM)

$41.54M

Trailing 12 months

Revenue growth YoY

+11.9%

Year over year

Operating margin

8.2%

Trailing 12 months

P / E (TTM)

227.7

Trailing earnings · reciprocal yield 0.4%

FCF yield

1.2%

TTM · current market cap

Return on invested capital

2.8%

Trailing 12 months

Net cash

$259.40M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.2%

Year over year · more shares

Price change (1Y)

+39.6%

Trailing year

Short interest

10.8%

Latest settlement · 6.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.7 · calm Equity put/call 0.48

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +19%

above

Price vs 50-day avg +8%

above

RSI (14) 51

neutral

MACD trend Negative

52-week position 83%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +3%

trailing

6-month return +41%

trailing

YTD return +3%

this year

Relative strength +27%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $156 › 200d $142 — 50d above 200d

Institutional flow Accumulating

+9% holders QoQ · +99 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

10.78% of float · ▼ -0.8% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

487 holders — near 3-yr high, broad support

Squeeze score 75

high risk · 0–100

Fundamentals

Excellent

Revenue growth +35%

Y/Y

EPS growth +287%

Y/Y

Free cash flow $93.9M

Buyback $25.0M

authorized

Balance sheet $23.8M

net cash

Quant / Vol

risk profile

Very High

Volatility 46%

annualized · 1-yr

Max drawdown −40%

past year

ATR 4.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 4

Latest guidance · from the 8-K filed Jul 28, 2026

Total Reported Revenue · FY 2026 Initiated $813M – $835M

prior FY $738.26M midpoint +11.6% Y/Y

Reported Growth · FY 2026 Initiated 10% – 13%

Organic Growth · FY 2026 Non-GAAP Initiated 10.5% – 13.5%

Gross Margin · FY 2026 Non-GAAP Initiated 53.7% – 54.2%

Income from Operations · FY 2026 Non-GAAP Initiated $128M – $134M

Other Income (Expense) · FY 2026 Non-GAAP Initiated $19M

Operating Margin · FY 2026 Non-GAAP Initiated 15.7% – 16%

Net Income · FY 2026 Non-GAAP Initiated $115.5M – $118.5M

Tax Rate on Pre-Tax Income · FY 2026 Non-GAAP Initiated 22%

Adjusted EBITDA Margin · FY 2026 Non-GAAP Initiated 20.6% – 21%

Earnings Per Share - Diluted · FY 2026 Non-GAAP Initiated $2.03 – $2.09

Prior guidance period ended · from the 8-K filed Jul 30, 2024

Total Reported Revenue · FY 2024 $620M – $635M

Base Revenue Growth · FY 2024 1%

Gross Margin · FY 2024 49% – 50%

Income from Operations · FY 2024 $12M – $17M

Income from Operations · FY 2024 $76M – $81M

Other Income (Expense) · FY 2024 $5M

Tax Rate on Pre-Tax Income · FY 2024 35%

Other Income (Expense) · FY 2024 $24M

Tax Rate on Pre-Tax Income · FY 2024 20%

Net Income · FY 2024 $9.5M – $13.5M

Net Income · FY 2024 $80M – $84M

Earnings Per Share - Diluted · FY 2024 $0.17 – $0.24

Earnings Per Share - Diluted · FY 2024 $1.42 – $1.49

Guided vs delivered · last 4 settled

Total Reported Revenue FY 2024

guided $620M – $635M

guided $620M – $635M $634.44M In line

Earnings Per Share - Diluted FY 2024

guided $0.17 – $0.24

guided $0.17 – $0.24 $-0.46 Miss −324.4%

Full year revenue 2022 full year

guided $800M – $830M

guided $800M – $830M $801.54M In line

Revenue full-year 2021

guided $655M – $665M

guided $655M – $665M $670.53M Beat +1.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+19% Bullish

Price vs 50-day avg

+8% Bullish

RSI (14)

51 Neutral

MACD trend

Negative Bearish

52-week position

83% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $156 › 200d $142 — 50d above 200d

Institutional flow Accumulating

+9% holders QoQ · +99 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

10.78% of float · ▼ -0.8% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

487 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $103 Now $169 · 83% Range high $182

vs 200-day avg +19% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RGEN Repligen Corp this stock	$9.31B	+2.8%	+35.1%	—	10.8%
ISRG Intuitive Surgical Inc	$124.11B	-38.2%	+20.5%	40.3	2.0%
BDX Becton Dickinson & Co	$48.89B	—	+8.2%	—	3.4%
MDLN Medline Inc.	$45.17B	-17.4%	+11.5%	—	2.8%
ALC Alcon Inc	$33.49B	-12.3%	+10.5%	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

487

% held: 118.4%
Net QoQ: +814.8K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

572

View

Short & Settlement

Short Interest Falling

Shares short

6.1M

Days to cover: 6.4d
Change: -47.2K sh

View

Short Volume

Short vol %

55%

As of: Sep 9, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $8.6K
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

48.8%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Oct 31, 2025

View

Financials

Revenue (FY)

$141.2M

Net income (FY): $48.9M
EPS diluted: $0.86

View

Buybacks

Authorized

$25.0M

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 9, 2026
This year: 14

View

Proposed Sales

Value

$503.5K

Shares: 3.0K
Filed: Sep 4, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
RGEN	-6.9%	+3.3%	+41.3%	-6.9%	+2.9%
SPY	-0.1%	-0.9%	+14.2%	-0.1%	+12.3%
vs SPY	-6.7%	+4.2%	+27.1%	-6.7%	-9.5%

Capital returns

Buyback program · as of Dec 31, 2023

Authorized

$25.00M

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 730272 CUSIP 759916109 13F (30d) 265 filings 263 filers Visit website Investor relations

RGEN · Repligen Corp

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns